Dr. Keith Keer on PD-L1 in Lung Cancer

Video

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Right now the only biomarker with validated data in lung cancer is PD-L1 immunohistochemistry. It is perceived as not being a good biomarker, but it is unfairly judged says Kerr.

It often gets compared to EGFR mutation or ALK translocation which are very effective biomarkers, but PD-L1 is not the only controlling factor within the immune response and it will never have the level of predictive power as those biomarkers. Expectations of PD-L1 need to be downgraded, says Kerr.

However, it can be improved. Right now each PD-L1 inhibitor has its own immunohistochemistry test and they are not all the same. It is not practical to do multiple test, so there needs to be simplification, says Keer.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD